Lorusso, Domenica

ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma

Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer

Endometrial and Cervical Cancer TreatmentsOvarian cancer diagnosis and treatment

Cited by 1,989

ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 1,197

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., et al. (2011) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentCancer Treatment and Pharmacology

Cited by 229

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Marth, C., Vergote, I., Scambia, G., Oberaigner, W., Clamp, A., Berger, R., Kurzeder, C., Colombo, N., Vuylsteke, P., Lorusso, D., et al. (2017) · European Journal of Cancer

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 79

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial

Mahner, S., Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell’Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., et al. (2015) · European Journal of Cancer

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 70

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial

Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., et al. (2012) · Annals of Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 69